Clinigen CTS Ltd

What Clinigen CTS Ltd does

Clinigen CTS Ltd is a UK-headquartered global pharmaceutical services company operating as part of Clinigen Group plc, providing access to medicines across three integrated pathways: clinical trial supplies, licensed commercial distribution, and pre-approval/unlicensed (managed) access programs. Its core offerings include the eCEMS clinical trial supplies management platform, comparator sourcing, packaging and labelling, global storage and distribution, biological sample management (biorepository, logistics, collection kits), and the Global Partnering service for licensed and unlicensed distribution across 130+ countries, with 6 million units shipped annually. The company runs more than 300 Early Access Programs covering rare conditions including rare cancers, and holds exclusive global distribution rights to specialty products such as Erwinase (crisantaspase), alongside Foscavir, Proleukin, Imukin, Gliadel, and Rezdiffra marketed in France via its Clinigen Healthcare France subsidiary.

Clinigen monetises through four primary streams: (1) licensing/royalty agreements with biotech and pharma partners for product commercialisation, exemplified by the €10.5M upfront MaaT Pharma license for European rights to MaaT013; (2) commercial product distribution generating transaction fees on licensed and named-patient medicines; (3) managed services fees for pre-approval access programs including regulatory compliance, pharmacovigilance, and global distribution; and (4) professional services revenue from clinical supplies management (comparator sourcing, packaging/labelling, QP release, controlled drug handling). Go-to-market is enterprise field sales via regional teams in the USA, Europe, Japan, Asia Pacific, and Africa, supplemented by industry events (CPhI Frankfurt 2025), thought leadership through the Centre of Excellence for Market Access & HEOR, patient advocacy programmes (NaviGATE), and the Clinigen Direct e-commerce portal for hard-to-find medicines. Distribution is executed through owned warehouses in the UK and Ireland (Clinigen Ireland Ltd), a partner warehouse with Yusen Logistics in Belgium, and regional operations across France, Germany, the US, Japan, Australia (via Link Healthcare), and South Africa.

The business is currently subject to a recommended takeover offer from Triley Bidco Limited, a vehicle indirectly owned by funds managed by Triton Investment Management, which would take Clinigen Group plc private. Operationally, Clinigen serves biotech and pharmaceutical manufacturers as enterprise customers (e.g., MaaT Pharma, Porton Biopharma), French hospital pharmacies (Erwinase supply), and patient advocacy groups, with regulatory relationships extending to ANSM, HAS, CEPS, MHRA, AIFA, and the EMA underpinning its compliant access programmes.

Name

Clinigen CTS Ltd

Legal name

Clinigen Group plc

Website

https://clinigengroup.com

Company type

Private

Founded year

2004

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Clinigen CTS Ltd is a UK-based global pharmaceutical services company providing clinical trial supplies, licensed distribution, and pre-approval managed access programmes to biotech, pharma manufacturers, and hospital pharmacies across 130+ countries.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceutical Services and Distribution

NAICS

Drugs and Druggists' Sundries Merchant Wholesalers (42421)

SIC

Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Pharmaceutical Preparations (2834)

akta.pro primary industry

Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK)

akta.pro secondary industries

Specialty Care Pharmaceuticals (HLAIAAAB), Medical Device Packaging (Trays, Clamshells, Kits) (IMALAIAD)

Keywords

• Pharmaceutical services
• Clinical trial supplies
• Managed access programs
• Pharmaceutical distribution
• Early access medicines

Headquarters

HQ city

Burton-on-trent

HQ country

United Kingdom

HQ region

Europe

Offices8 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure, Supply Chain

Revenue model

1. License agreements: Clinigen signs licensing agreements with biotech/pharmaceutical companies for commercialization of their products. Example: €10.5 million upfront license agreement with MaaT Pharma for European commercialization of MaaT013.
2. Commercial product distribution: Distribution and sale of commercial pharmaceutical products including licensed medicines (Erwinase, Foscair, Imukin, Proleukin, Gliadel, Rezdiffra) and unlicensed medicines for named patient programs.
3. Managed Access services: Provides pre-approval access programs enabling patients to access investigational medicinal products outside clinical trials. Services include regulatory compliance, pharmacovigilance, and distribution for early access programs.
4. Clinical services: Clinical trial supplies management including comparator sourcing, packaging and labelling, global storage and distribution, QP services, and biological sample management.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels5 records

Core offering

Clinigen CTS Ltd is a global specialist pharmaceutical services and products platform that supplies drugs and ancillaries for clinical trials, manages pre-approval and compassionate use access programs for investigational medicines, and distributes licensed and unlicensed medicines worldwide. Its offering spans clinical trial supplies management (via the proprietary eCEMS platform), biological sample management, Managed Access Programs enabling patient access to investigational therapies before formal approval, global partnering for licensed and unlicensed distribution, and commercial distribution of specific in-licensed pharmaceutical products.

Product overview

Clinigen CTS Ltd operates as a global specialist pharmaceutical services platform providing access to medicines across three pathways: clinical trials, licensed medicines, and pre-approval/unlicensed access. The portfolio consists of multiple integrated service lines and proprietary platforms. The core offerings include: (1) eCEMS, a clinical trial supplies management platform for tracking and managing clinical supply chain operations; (2) Clinical Trial Supplies Services encompassing packaging, labelling, comparator sourcing, storage/distribution, and supply chain management; (3) Managed Access Programs (also known as Early Access Programs/EAPs) enabling patient access to investigational medicines before formal authorization; (4) Biological Sample Management services including biorepository, logistics, and collection kits; (5) Global Partnering for licensed and unlicensed distribution; and (6) the Navigate Program for patient advocacy training in rare diseases. The company also commercializes specific pharmaceutical products including Erwinase, Foscavir, Proleukin, Imukin, GLIADEL, and Rezdiffra through its French operations. Additional offerings include a Centre of Excellence for Market Access & HEOR providing thought leadership, Clinigen Direct for online medicine access, and Exploitant Services for French market regulatory and commercial support.

Differentiator

Problem solved

Functional benefit

Brands

• eCEMS: Clinical trial supplies management platform
• Navigate
• Clinigen Direct
• Centre of Excellence for Market Access & HEOR

Products and services

• Clinical Trial Supplies Services Comprehensive services for clinical trial supply management including packaging and labelling, comparator sourcing, on-demand sourcing, global storage and distribution, clinical supply chain management, returns reconciliation and destruction, QP services, controlled drug services, and specialty services. For pharmaceutical sponsors and CROs conducting clinical trials.
• eCEMS Clinical Trial Supplies Management Platform Digital platform for managing clinical trial supplies, enabling tracking, ordering, and management of clinical supply chain operations. Used by clinical trial sponsors and CROs.
• Managed Access Programs Pre-approval and Managed Access programs enabling patients to access investigational medicinal products outside clinical trials before official marketing. Includes Early Access Programs, Compassionate Use, Named Patient Use, Expanded Access, and Unlicensed Access. For patients with serious or life-threatening conditions and the pharma companies providing investigational therapies.
• Early Access Programs (EAPs) Ethical, compliant, and controlled mechanisms for patients to access investigational medicinal products outside the clinical trial space before formal marketing. Designed for patients with life-threatening diseases who meet specific criteria. Over 300 EAPs running globally covering rare conditions including rare cancers.
• Biological Sample Management Services including biorepository services, biological sample logistics, and biological sample collection kits for managing biological samples during clinical trials. For clinical trial sponsors and research organizations.
• Global Partnering (Licensed and Unlicensed Distribution) Distribution services for both licensed and unlicensed medicines across global markets, enabling pharmaceutical access in licensed and unlicensed markets worldwide. For pharmaceutical and biotech companies seeking commercialization partners.
• Clinigen Direct Online platform for healthcare professionals to access information about hard-to-find medicines and products distributed by Clinigen. For healthcare professionals seeking access to unlicensed or hard-to-find medicines.
• Navigate Program Educational initiative providing navigational support and tools to help rare disease patient groups engage with healthcare providers, industry and regulatory bodies on early access programs. Co-created with Flutters & Strutters, RARE Revolution Magazine, and CRD Consulting Ltd. For rare disease patient advocacy groups.
• Exploitant Services (France) Comprehensive regulatory, pharmacovigilance, medical information, distribution, and sales services for pharmaceutical products in the French market, including lifecycle management of marketing authorization dossiers, reimbursement dossiers, price negotiation, and sales representative certification. For pharmaceutical companies seeking French market entry and commercialization.
• Erwinase (crisantaspase) A licensed pharmaceutical product (L-asparaginase Erwinia chrysanthemi) used in the treatment of acute lymphoblastic leukaemia (ALL) for patients unable to tolerate E. coli-derived asparaginase. Clinigen is the exclusive global distributor. For hospital pharmacies and ALL patient treatment.

Quantifiable outcome

• Accelerated access to medicines in 130+ countries
• +2 more outcomes

Named customers4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Ten partnerships are on record, tiered core and minor.

• MaaT PharmacoreStrategic or Co-development Partner · 1 January 2025MaaT Pharma signed a €10.5 million upfront license agreement with Clinigen for European commercialization of MaaT013 (Xervyteg®). Clinigen will leverage its established infrastructure and expertise to support regulatory engagement and commercialization following MaaT Pharma's MAA submission to EMA in June 2025.
• Yusen LogisticscoreChannel Partner/ Reseller/ DistributorLong-established partnership with Yusen Logistics (Benelux) providing distribution services for EEA customer supply. Yusen manages subcontracting of these services. Address: Keetberglaan 1, 9120 Melsele, Belgium. WDA 1768 H.
• Link HealthcareminorChannel Partner/ Reseller/ DistributorRegional partnership for Australian market - Link Healthcare operates as Clinigen Australia regional site (linkhealthcare.com.au).
• Porton Biopharma LimitedcoreStrategic or Co-development PartnerPorton Biopharma Limited is the exclusive manufacturer of Erwinase® (crisantaspase). Clinigen is the exclusive global distributor of Erwinase. Porton has confirmed cessation of manufacturing towards end of 2025.
• Flutters & Strutters Patient Advocacy OrganisationcoreStrategic or Co-development PartnerCo-creation partner for NaviGATE educational program - a training initiative for patient advocacy groups and patients to navigate early access programs. Co-created with RARE Revolution Magazine and Michelle Conway of CRD Consulting Ltd.
• RARE Revolution MagazinecoreStrategic or Co-development PartnerCo-creation partner for NaviGATE educational program - a training initiative for patient advocacy groups and patients to navigate early access programs.
• CRD Consulting LtdminorStrategic or Co-development PartnerConsulting partner for NaviGATE program development with Michelle Conway as representative.
• ANSM (French National Agency for Medicines and Health Products Safety)coreOthersStrong regulatory relationships with ANSM for smooth and efficient market entry and approval processes in France. Collaboration on early access programs (Accès Précoce) and compassionate use (Accès Compassionnel).
• HAS (High Authority of Health)coreOthersStrategic partnership with HAS for alignment with national health priorities and guidelines, and for early access program authorization.
• CEPS (Economic Committee for Health Products)coreOthersStrong relationships with CEPS to support negotiation and achieve favorable pricing and reimbursement conditions for products in France.

Scale indicators6 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Catalent: Major global CDMO and clinical trial supply services provider offering comparator sourcing, packaging, labelling, and global distribution — directly overlapping with Clinigen's CTS division and biologic sample management offerings.
• PCI Pharma Services: Specialty pharma services platform providing clinical trial supply, commercial packaging, and global distribution. Closely comparable to Clinigen on packaging/labelling, comparator sourcing, and specialty pharma commercialization.
• Marken (UPS Healthcare): Global clinical trial supply chain logistics provider offering direct-to-patient delivery, biological sample management, and comparator sourcing — direct overlap with Clinigen's biological sample management and global storage/distribution lines.

Broad incumbents

• IQVIA: Diversified CRO and commercial services giant offering clinical trial supplies alongside broader CRO and commercial launch services. Overlaps with Clinigen across clinical services and global commercialization, though IQVIA is far broader in scope.
• ICON plc: Global CRO with clinical trial services and bioanalytical lab capabilities. Comparable to Clinigen's clinical services line as a broad incumbent offering clinical trial support.
• Thermo Fisher Scientific (PPD Clinical Research Services): Through PPD, Thermo Fisher offers end-to-end clinical development services including clinical trial supplies and comparator sourcing, competing broadly with Clinigen's CTS and lifecycle services offerings.
• Syneos Health: Combined CRO and commercial services provider with clinical supply and commercialization capabilities — competes with Clinigen across clinical trial supplies and European commercialization services.
• Worldwide Clinical Trials: Mid-tier global CRO offering clinical trial services across multiple therapeutic areas. Comparable to Clinigen as a broad clinical services provider, though without the managed access commercialization line.

Emerging players

• myTomorrows: Specialized patient access platform focused on early access and expanded access programs for investigational medicines. Closely comparable to Clinigen's Managed Access Programs line, though smaller in scale and geographic reach.
• WEP Clinical: Specialty pharma services company focused on early access and managed access programs plus unlicensed medicine distribution. Direct niche overlap with Clinigen's Global Partnering unlicensed distribution line.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/clinigen-group

Revenue estimate

Valuation estimate

Number of profiles

Profiles21 records

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Clinigen CTS Ltd